Press Releases

XORTX Announces Pre-Phase 3 Meeting Request with US Food and Drug Administration (FDA)

XORTX Announces “Fireside Chat” with XORTX CEO

XORTX to Present at BIO International Convention 2022

XORTX to Present at LD Micro Invitational 2022

XORTX Welcomes New Member to the Board of Directors and Appoints Chair

XORTX to Present at H. C. Wainwright Global Investment Conference 2022

XORTX Opens an IND for XRx-008 Program for Autosomal Dominant Polycystic Kidney Disease

XORTX Initiates Dosing of Human Subjects in the XRX-OXY-101 Clinical Trial

XORTX Receives Small and Medium Enterprise Status for the European Union

XORTX Receives No Objection Letter from Health Canada